United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Applied Materials

Coinbase

Intel

StoneCo

Altria

Novartis

Patient investors who overcome short-term distractions will get a windfall with these stocks to buy, as they're set to grow at a faster pace. The post 7 Stocks to Buy That Will Make You Rich by 2030 appeared first on InvestorPlace.

7 Stocks to Buy That Will Make You Rich by 2030

Amgen

Clover Health Investments

CVS Health

These health care industry players continue to serve the masses amid the current pandemic.

Hot Stocks To Buy Now? 4 Health Care Stocks To Know

The pharmaceutical giant has lagged the market over the past decade, but will the fight against COVID-19 change that?

Pfizer: Bull vs. Bear

Alibaba

Johnson & Johnson

Merck

Royal Dutch Shell's pension fund exited an investment in Alibaba, and slashed positions in Pfizer, Johnson & Johnson, and Merck in the third quarter.

Shell's Pension Dropped Alibaba and Sold Big Pharma Stocks

Pfizer's COVID Franchise fuels accelerated growth across all its business lines.

Pfizer's Premier COVID Franchise Lays The Foundation For Continued Outsized Returns

Here is yet another day when an ARK Invest exchange-traded fund run by ETF star Cathie Wood parted with even more Pfizer Inc.

Cathie Wood's ARK Invest Sells Over 400,000 More Shares of Pfizer

Eli Lilly

Two of them have already been big winners for investors this year.

3 Pharma Stocks That Could Make You Richer in November (and Beyond)

A day after one ARK Invest exchange-traded fund run by ETF star Cathie Wood parted with more than $11 million worth of Pfizer Inc.

Cathie Wood's ARK Invest Sells Over 140,000 More Shares of Pfizer

How Pfizer Knocked It Out of the Park in Q3

BioNTech SE

The last decade has been a challenging one for value investors. Prior to the fourth quarter of 2020, value stocks (MSCI World Value) had been experiencing their longest and most pronounced underperformance period on record relative to growth stocks (MSCI World Growth).

Brandes: The Staying Power of the Value Run

Before investing in Pfizer, read here to understand their core business, company history and relevant news developments.

Investing in Pfizer Stock (PFE)

Pfizer continues to demonstrate its superiority in the COVID-19 vaccines market against its peers.

Pfizer Stock: How Will Recent Earnings Results Impact The Stock Going Forward

Pfizer has a robust pipeline totaling 94 drugs, 29 of which are in phase 3 studies. Vyndaqel/Vyndamax, Eliquis, and the company's portfolio of oncology biosimilars are experiencing rapid growth.

The Outlook For Pfizer Stock: A COVID-19 Pill And Children's Vaccines

One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 230,000 shares of Pfizer Inc.

Cathie Wood's ARK Invest Sells Over 230,000 Shares of Pfizer

Bristol-Myers

Now may be a good time to buy these healthcare dividend giants.

3 Rock-Solid Healthcare Dividend Stocks Now on Sale

It probably means another billion-dollar opportunity is on the way.

Could Pfizer's COVID Pill Be Even Bigger Than Its Vaccine?

The agency is expected to grant Pfizer's request​, perhaps before Thanksgiving, says a report.

Pfizer asks FDA to authorize booster for all adults

Amazon

DoorDash

Moderna

Regeneron Pharmaceuticals

AMC Entertainment

Cisco Systems

Zoom Video

More than a year and a half into the Covid-19 pandemic, the world is changing. More people are returning to the office after months of working at home and restaurants have reopened.

10 Stocks Post-Pandemic: What to Consider, Keep and Run From

Pfizer Inc. PFE, -2.03% said Tuesday that it is asking the Food and Drug Administration to authorize its COVID-19 booster for all adults in the U.S. This is the second time that the company and BioNTech SE BNTX, -5.69% have asked the regulator to OK boosters for all adults. Back in August, the companies originally sought full FDA approval for their booster in individuals who are at least 16 years old; however, the FDA changed the approval request to an authorization and limited boosters to the elderly, adults at high risk of severe disease, and those who have jobs that put them at high risk, based on the recommendation of an advisory committee.

Pfizer asks FDA to authorize COVID-19 booster shot for all adults

Pfizer said it asked the FDA to authorize booster shots of its Covid-19 vaccine for all Americans age 18 and older.

Pfizer asks FDA to authorize Covid booster shots for all adults

"They're criminals because they have literally cost millions of lives," Pfizer CEO Albert Bourla said.

Pfizer CEO says people who spread misinformation on Covid vaccines are 'criminals'

Biohaven Pharmaceutical Hld

Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) and Pfizer Inc (NYSE: PFE) have announced an agreement for rimegepant in markets outside the U.S. Rimegepant is commercialized as Nurtec ODT in the U.S. and is indicated for the acute treatment of migraine attacks with or without aura and the preventive treatment of episodic migraine in adults.

Pfizer Gains Outside US Rights To Biohaven's Migraine Treatment For $500M

Shares of Biohaven Pharmaceutical Holding Company Ltd. BHVN, -4.29% tumbled 15.2% in premarket trading on Tuesday after it announced a deal worth up to $1.2 billion with Pfizer Inc. PFE, -0.58% to commercialize the company's migraine treatment outside of the U.S. Pfizer's stock was down 0.4% in trading before the market opened on Tuesday.

Biohaven's stock slides 15% on deal with Pfizer for its migraine drug

Better COVID Stock: Merck vs. Pfizer

The stock price of Pfizer surged 11% in a single day on Friday Nov 5, 2021. The rise can be attributed to the company announcing positive data for its oral pill for the treatment of Covid-19.

News for Pfizer Stock (PFE)